Literature DB >> 27183097

Could renal impairment be a positive predictor of outcome in autografts for myeloma?

J Szer1.   

Abstract

Entities:  

Mesh：

Year:  2016        PMID： 27183097     DOI： 10.1038/bmt.2016.138

Source DB:  PubMed          Journal:  Bone Marrow Transplant        ISSN： 0268-3369            Impact factor:   5.483


× No keyword cloud information.
  8 in total

1.  Prospective randomised trial of amifostine cytoprotection in myeloma patients undergoing high-dose melphalan conditioned autologous stem cell transplantation.

Authors:  A Spencer; N Horvath; J Gibson; H M Prince; R Herrmann; J Bashford; D Joske; A Grigg; J McKendrick; I Prosser; R Lowenthal; S Deveridge; K Taylor
Journal:  Bone Marrow Transplant       Date:  2005-05       Impact factor: 5.483

Review 2.  Optimizing the treatment of patients with multiple myeloma and renal impairment.

Authors:  Norbert Grzasko; Marta Morawska; Marek Hus
Journal:  Clin Lymphoma Myeloma Leuk       Date:  2014-10-05

3.  Intravenous busulfan and melphalan as a conditioning regimen for autologous stem cell transplantation in patients with newly diagnosed multiple myeloma: a matched comparison to a melphalan-only approach.

Authors:  Margarita Blanes; Juan J Lahuerta; José D González; Paz Ribas; Carlos Solano; Adrían Alegre; Joan Bladé; Jesús F San Miguel; Miguel A Sanz; Javier de la Rubia
Journal:  Biol Blood Marrow Transplant       Date:  2012-08-13       Impact factor: 5.742

4.  Melphalan 200 mg/m2 in patients with renal impairment is associated with increased short-term toxicity but improved response and longer treatment-free survival.

Authors:  K Sweiss; S Patel; K Culos; A Oh; D Rondelli; P Patel
Journal:  Bone Marrow Transplant       Date:  2016-05-16       Impact factor: 5.483

5.  High busulfan exposure is associated with worse outcomes in a daily i.v. busulfan and fludarabine allogeneic transplant regimen.

Authors:  Michelle Geddes; S Bill Kangarloo; Farrukh Naveed; Diana Quinlan; M Ahsan Chaudhry; Douglas Stewart; M Lynn Savoie; Nizar J Bahlis; Christopher Brown; Jan Storek; Borje S Andersson; James A Russell
Journal:  Biol Blood Marrow Transplant       Date:  2008-02       Impact factor: 5.742

6.  A randomized study of melphalan 200 mg/m(2) vs 280 mg/m(2) as a preparative regimen for patients with multiple myeloma undergoing auto-SCT.

Authors:  W I Bensinger; P S Becker; T A Gooley; T R Chauncey; D G Maloney; A K Gopal; D J Green; O W Press; M Lill; J J Ifthikharuddin; R Vescio; L A Holmberg; G L Phillips
Journal:  Bone Marrow Transplant       Date:  2015-09-14       Impact factor: 5.483

Review 7.  High-dose intravenous melphalan: a review.

Authors:  B L Samuels; J D Bitran
Journal:  J Clin Oncol       Date:  1995-07       Impact factor: 44.544

8.  Efficacy, toxicity and mortality of autologous SCT in multiple myeloma patients with dialysis-dependent renal failure.

Authors:  R St Bernard; L Chodirker; E Masih-Khan; H Jiang; N Franke; V Kukreti; R Tiedemann; S Trudel; D Reece; C I Chen
Journal:  Bone Marrow Transplant       Date:  2014-10-06       Impact factor: 5.483
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.